Oruka Therapeutics, Inc. (NASDAQ:ORKA) Shares Sold by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. trimmed its position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 65.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 69,200 shares of the company's stock after selling 130,800 shares during the period. Adage Capital Partners GP L.L.C. owned approximately 0.20% of Oruka Therapeutics worth $1,342,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. FMR LLC boosted its position in shares of Oruka Therapeutics by 17.7% in the 4th quarter. FMR LLC now owns 5,512,300 shares of the company's stock worth $106,883,000 after purchasing an additional 830,000 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Oruka Therapeutics by 4,161.2% in the 4th quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock valued at $31,231,000 after purchasing an additional 1,572,853 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Oruka Therapeutics by 374.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,326,893 shares of the company's stock worth $25,730,000 after purchasing an additional 1,047,245 shares in the last quarter. Franklin Resources Inc. acquired a new position in Oruka Therapeutics during the 3rd quarter valued at approximately $17,661,000. Finally, SR One Capital Management LP raised its holdings in shares of Oruka Therapeutics by 14.7% in the fourth quarter. SR One Capital Management LP now owns 430,330 shares of the company's stock worth $8,344,000 after buying an additional 55,000 shares during the last quarter. 56.44% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Oruka Therapeutics

In related news, major shareholder Venrock Healthcare Capital Par bought 8,971 shares of the business's stock in a transaction dated Wednesday, February 12th. The stock was acquired at an average price of $11.86 per share, with a total value of $106,396.06. Following the completion of the purchase, the insider now directly owns 4,044,684 shares of the company's stock, valued at approximately $47,969,952.24. This trade represents a 0.22 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last three months, insiders have acquired 98,339 shares of company stock valued at $1,128,456. Company insiders own 22.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ORKA. HC Wainwright reissued a "buy" rating and set a $45.00 price objective on shares of Oruka Therapeutics in a report on Friday, February 7th. Wedbush reissued an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a report on Friday, March 7th. Finally, Wolfe Research began coverage on Oruka Therapeutics in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $39.86.

Oruka Therapeutics Stock Performance

NASDAQ ORKA traded down $0.60 during mid-day trading on Monday, reaching $10.11. 38,437 shares of the stock were exchanged, compared to its average volume of 233,272. The company has a market capitalization of $378.53 million, a P/E ratio of -1.62 and a beta of 0.25. The business's 50 day moving average is $9.99 and its 200-day moving average is $16.07. Oruka Therapeutics, Inc. has a 1 year low of $5.49 and a 1 year high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its earnings results on Thursday, March 6th. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.19. Equities analysts predict that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.